mobirise.com

Transference to
companies and hospitals

A fundamental aspect of our work is the validation of the transcription factor NRF2 as a new therapeutic target for chronic diseases and in particular Parkinson and Alzheimer and amyotrophic lateral sclerosis.

Our group brings to the biopharmaceutical industry preclinical mouse models of Parkinson's disease (PD) and Alzheimer's (AD). In spite of having "cured" these diseases in rodents with multiple pharmacological approaches, in clinical practice these studies have failed. We have developed models that are far superior to the present ones, where aging and comorbidities associated with PD and AD can be reproduced with deficiency in NRF2 (knockout mouse) expressing the own proteinopathy of each disease.
.

Colaborations with companies

Our laboratory provides pharmacological research services in preclinical models of neuroprotection.

For PD, we have toxic (MPTP and 6-hydroxydopamine) and genetic models (steroidic surgery of adeno-associated vectors for alpha-synuclein expression: AAV-alpha-SYN).

For AD, we have a mouse developed by our group that expresses amyloidopathy and tauopathy in the presence and absence of NRF2. We also have a model of tauopathy based on expression of an AAV-TAU vector in mouse hippocampus.

We have collaborated with companies of national (Neurofarma/Noscira) and international (Biogen Inc, Evgen Pharma and Acipse) scopes in the validation of their drugs in preclinical models of PD.

Within the framework of the European Union H2020 projects, we maintain contacts with several SMEs interested in our preclinical models.

To consider possible collaborations see the contact section at the bottom.

Colaborations with hospitals

Our laboratory belongs to the Instituto de Investigación Saniaria La PAZ (IDIPAZ). Within the area of Neuroscience we forme the group called: Neuroprotective Strategies in Neurodegenerative Diseases".

Our group also belongs to the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Within this institution we collaborate with pathologists of the Tissue Bank of Fundación Reina Sofia for Alzheimer's Disease.

Our group also collaborates with the Department of Neurology of Hospital Clínico San Carlos, Madrid. A recent collaboration funded by Fundación Tatiana Pérez de Guzmán el Bueno has allowed us to join forces with Dr. Jorge Matias-Guiu and Lucía Galán to define the role of NRF2-related pathomechanisms in amyotrophic lateral sclerosis. This project is led by Dr. Ana I. Rojo.

A recent collaboration with Dr. Gerard Piñol Ripol from the Unitat Trastorns Cognitius, Hospital Universitari Santa Maria Lleida, Lleida, Spain, has allowed us to collaborate with teams of DEGESCO (Dementia Genetics Spanish Consortium) on biomarker discovery related to the transcriptional signature of NRF2 and NF-kB in blood of subjects undergoing mild cognitive impairment to advanced dementia.

At the international level, we work on the identification of new biomarkers of progression, prognosis and therapeutic efficacy in peripheral blood in patients with mild cognitive impairment and early Alzheimer's disease. This study is part of the European REDBRAIN project of which Dr. Antonio Cuadrado is principal investigator. As part of REDBRAIN we are now collaborating with Dr. Jordi Matias-Guiu form the Department of Neurology of Hospital Clínico San Carlos, Madrid.

Patents


 Rafael León; Javier Egea; Izaskun Buendía; Esther Parada; Elisa Navarro; Patricia Rada; Antonio Cuadrado; Antonio G. García; Manuela G. López. P201400810. Compuestos derivados de acrilato de 3-alquilamino-1H-indolilo y su uso en el tratamiento de enfermedades neurodegenerativas. España. 15/10/2014. Hospital Universitario de La Princesa. Consejo Superior de Investigaciones Científicas; DNS Neuroscience, S.A.; Universidad Autónoma de Madrid.

Rafael León; Javier Egea; Izaskun Buendía; Esther Parada; Elisa Navarro; Patricia Rada; Antonio G. García; Antonio Cuadrado; Manuela G. López. P201300667. Uso del 3-(2-isotiocianatoetil)-5-metoxi-1H-indol para el tratamiento de enfermedades neurodegenerativas.. España. 17/07/2013. Hospital Universitario de La Princesa. Consejo Superior de Investigaciones Científicas; DNS Neuroscience, S.A.; Universidad Autónoma de Madrid.

Antonio Cuadrado; Nadia G. Innamorato. P201231693. Uso del sulforafano como terapia suplementaria de la fase temprana de una enfermedad neurodegenerativa. España. 15/04/2013. Universidad Autónoma de Madrid. Neuroscience, S.A.

Home

Research

Recent Publications

Companies & hospitals

Team

Donations